Concord Drugs Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 156.42 million compared to INR 123.06 million a year ago. Revenue was INR 156.44 million compared to INR 123.07 million a year ago. Net loss was INR 3.39 million compared to net income of INR 1.63 million a year ago. Basic loss per share from continuing operations was INR 0.34 compared to basic earnings per share from continuing operations of INR 0.17 a year ago. Diluted loss per share from continuing operations was INR 0.34 compared to diluted earnings per share from continuing operations of INR 0.17 a year ago.
For the full year, sales was INR 449.25 million compared to INR 520.81 million a year ago. Revenue was INR 449.34 million compared to INR 520.89 million a year ago. Net income was INR 4.72 million compared to INR 9.86 million a year ago. Basic earnings per share from continuing operations was INR 0.47 compared to INR 1.06 a year ago. Diluted earnings per share from continuing operations was INR 0.47 compared to INR 1.06 a year ago.